Altundag K et al. Adjuvant trastuzumab use in high-risk breast cancer patients may prevent development of contralateral estrogen receptor-negative breast tumors. Med Hypotheses 2005;[Epub ahead of print]. No abstract available

Bianco AR. Targeting c-erbB2 and other receptors of the c-erbB family: Rationale and clinical applications. J Chemother 2004;16(Suppl 4):52-4. Abstract

Chen EX, Siu LL. Development of molecular targeted anticancer agents: Successes, failures and future directions. Curr Pharm Des 2005;11(2):265-72. Abstract

Cobleigh MA et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30(5 Suppl 16):117-24. Abstract

De Laurentiis M et al. Targeting HER2 as a therapeutic strategy for breast cancer: A paradigmatic shift of drug development in oncology. Ann Oncol 2005;(16 Suppl 4):iv7- iv13. Abstract

Emens LA. Trastuzumab: Targeted therapy for the management of HER-2/neuoverexpressing metastatic breast cancer. Am J Ther 2005;12(3):243-53. Abstract

Geyer CE Jr et al. Cardiac safety analysis of the f irst stage of NSABP B-31, a randomized trial comparing the safety and eff icacy of Adriamycin and cyclophosphamide (AC) followed by Taxol to that of AC followed by Taxol plus Herceptin in patients (Pts) with operable, node-positive (N+), HER-2 overexpressing breast cancer (HER2+BC). San Antonio Breast Cancer Symposium 2003;Abstract 23.

Hampton T. Monoclonal antibody therapies shine in breast cancer clinical trials. JAMA 2005;293(24):2985-9. No abstract available

Hudis CA. Clinical implications of antiangiogenic therapies. Oncology (Williston Park) 2005;19(4 Suppl 3):26-31. Abstract

Ignoffo RJ. Overview of bevacizumab: A new cancer therapeutic strategy targeting vascular endothelial growth factor. Am J Health Syst Pharm 2004;61(21 Suppl 5):21-6. Abstract

Kaklamani V, O’Regan RM. New targeted therapies in breast cancer. Semin Oncol 2004;31(2 Suppl 4):20-5. Abstract

Klein PM, Dybdal N. Trastuzumab and cardiac dysfunction: Update on preclinical studies. Semin Oncol 2003;30(5 Suppl 16):49-53. Abstract

Miller KD. Recent translational research: Antiangiogenic therapy for breast cancer — Where do we stand? Breast Cancer Res 2004;6(3):128-32. Abstract

Miller KD et al. E2100: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as f irst-line therapy for locally recurrent or metastatic breast cancer. Presentation. ASCO 2005a. No abstract available

Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005b;23(4):792-9. Abstract

Moses MA et al. A role for antiangiogenic therapy in breast cancer. Curr Oncol Rep 2004;6(1):42-8. Abstract

Perez EA et al. Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial. Proc ASCO 2005a;Abstract 556.

Perez EA et al. NCCTG N9831: May 2005 update. Presentation. ASCO 2005b;Abstract 556.

Piccart-Gebhart MJ. First results of the HERA trial. Presentation. ASCO 2005. No abstract available

Rhee J, Hoff PM. Angiogenesis inhibitors in the treatment of cancer. Expert Opin Pharmacother 2005;6(10):1701-11. Abstract

Romond EH et al. Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer — Combined analysis of NSABP-B31/NCCTG-N9831. Presentation. ASCO 2005. No abstract available

Rueckert S et al. A monoclonal antibody as an effective therapeutic agent in breast cancer: Trastuzumab. Expert Opin Biol Ther 2005;5(6):853-66. Abstract

Rugo HS. Bevacizumab in the treatment of breast cancer: Rationale and current data. Oncologist 2004;9(Suppl 1):43-9. Abstract

Schneider BP, Miller KD. Angiogenesis of breast cancer. J Clin Oncol 2005;23(8):1782-90. No abstract available

Seidman A et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20(5):1215-21. Abstract

Suter TM et al. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast 2004;13(3):173-83. Abstract

Willems A et al. Antibody therapy for breast cancer. Anticancer Res 2005;25(3A):1483-9. Abstract